Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma

Liu,Hong; Xu,Ruirong; Huang,Hongming

doi:10.3892/etm.2016.3738

Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma

Authors:
- Hong Liu
- Ruirong Xu
- Hongming Huang
View Affiliations

Affiliations: Department of Hemopathology, Huai'an First People's Hospital, Huai'an, Jiangsu 223300, P.R. China, Department of Hematopathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: September 21, 2016 https://doi.org/10.3892/etm.2016.3738
Pages: 3041-3046

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to the safety, convenience and efficacy of subcutaneous administration of bortezomib (scBor), it is becoming increasingly common to treat multiple myeloma (MM) using this treatment method. The current retrospective study suggested a lower incidence of peripheral neuropathy (PN) outcomes and superior efficacy following treatment with scBor combined with thalidomide and dexamethasone (VTD) in MM when compared with intravenous Bor (ivBor) treatment. The data of 81 patients from the Affiliated Hospital of Nantong University between September 2011 and February 2014 were analyzed, including 37 scBor and 44 ivBor patients administered a median (range) of 5.5 (3‑8) and 6 (3‑10) chemotherapy cycles, respectively. Adverse events (AEs) were assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs, and response and progression were assessed by the International Myeloma Working Group criteria. Evidence of histopathology using transmission electron microscopy (TEM) was obtained from an in vivo model of adult Sprague Dawley (SD) rats. Following bortezomib‑based VTD chemotherapy, patients had achieved very good partial remission or demonstrated no significant difference between the scBor and ivBor treatment groups (75.6 vs. 84.1%, respectively; P=0.350). The 1‑year progression‑free survival (83.8 vs. 84.1%, scBor vs. ivBor; P=0.921) and 1‑year overall survival (OS) (91.9 vs. 90.9%, respectively; P=0.926) were also similar. PN rates of all the NCI grades were 51.3 and 61.3% (P=0.371); grade ≥2, 35.1 and 56.8% (P=0.052); and grade ≥3, 32.7 and 20.5% (P=0.015) in the subcutaneous and intravenous treatment groups, respectively, which suggests that severe PN may be less common following scBor treatment. There were no severe injection site reactions in the scBor‑treated group. The incidence of adverse events were comparable between the two groups, including thrombocytopenia, anemia, fatigue and gastrointestinal symptoms such as nausea and vomiting. Furthermore, TEM images of the SD rat sciatic nerves revealed that all rats suffered PN to varying degrees, except the control group, and that the PN of ivBor‑treated rats (in the presence and the absence of thalidomide) was more severe than that of scBor‑treated rats. It was concluded that a subcutaneous dose of bortezomib of 1.3 mg/m2 may result in a lower incidence and severity of PN, with equivalent efficacy, as a component of combination VTD chemotherapy.

View Figures

View References

1	Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S, Gillett D and Møller H: Consultant Haematologists, South Thames Haematology Specialist Committee: A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol. 127:299–304. 2004. View Article : Google Scholar : PubMed/NCBI
2	Pantani L, Zamagni E, Zannetti BA, Pezzi A, Tacchetti P, Brioli A, Mancuso K, Perrone G, Rocchi S, Tosi P and Cavo M: Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: Analysis of long-term clinical outcomes. Ann Hematol. 93:123–128. 2014. View Article : Google Scholar : PubMed/NCBI
3	Moreau P, Pylypenko H, Grosicki S, Karamanesht L, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, et al: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol. 12:431–440. 2011. View Article : Google Scholar : PubMed/NCBI
4	Soriano GP, Besse L, Li N, Kraus M, Besse A, Meeuwenoord N, Bader J, Everts B, den Dulk H, Overkleeft HS, Florea BI and Driessen C: Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia. 2016. View Article : Google Scholar : PubMed/NCBI
5	Ri M: Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy. Rinsho Ketsueki. 57:537–45. 2016.PubMed/NCBI
6	Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E, Couturier C, Mazier MA, Angermund R and Facon T: Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica. 98:1264–72. 2013. View Article : Google Scholar : PubMed/NCBI
7	Arnulf B, Pylypenko H, Grosicki S, Karamanesht L, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W and Moreau P: Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 97:1925–1928. 2012. View Article : Google Scholar : PubMed/NCBI
8	Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf I and Gorschlüter M: A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 132:584–593. 2006. View Article : Google Scholar : PubMed/NCBI
9	Palumbo A, Davies F, Kropff M, Bladé J, Delforge M, da Costa F Leal, Sanz R Garcia, Schey S, Facon T, Morgan G and Moreau P: Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Ann Hematol. 89:803–811. 2010. View Article : Google Scholar : PubMed/NCBI
10	Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, et al: International uniform response criteria for multiple myeloma. Leukemia. 20:1467–1473. 2006. View Article : Google Scholar : PubMed/NCBI
11	National Cancer Institute, . Common terminology criteria for adverse events, version 3.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfAccessed. April 11–2011
12	Greipp PR, San MJ, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, et al: International staging system for multiple myeloma. J Clin Oncol. 23:3412–20. 2005. View Article : Google Scholar : PubMed/NCBI
13	Hoy SM: Subcutaneous bortezomib: In multiple myeloma. Drugs. 73:45–54. 2013. View Article : Google Scholar : PubMed/NCBI
14	Grosicki S: Subcutaneous bortezomib as a new promising way to successful maintenance therapy in multiple myeloma. Wiad Lek. 65:167–173. 2012.(In Polish). PubMed/NCBI
15	Garderet L, Iacobelli S, Moreau P, Dib M, Niederwieser D, Masszi T, Fontan T, Michallet M, Gratwohl A, Lafon I, et al: Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: The MMVAR/IFM 2005-04 Randomized phase III trial from the chronic leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol. 30:2475–2482. 2012. View Article : Google Scholar : PubMed/NCBI
16	Tacchetti P, Terragnac C, Galli M, Zamagni E, Petrucci MT, Pezzi A, Montefusco V, Martello M, Tosi P, Baldini L, et al: Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: Clinical and molecular analyses of a phase 3 study. Am J Hematol. 89:1085–1091. 2014. View Article : Google Scholar : PubMed/NCBI
17	Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, et al: Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline. Br J Haematol. 144:895–903. 2009. View Article : Google Scholar : PubMed/NCBI
18	Lamm W, Drach-Schauer B, Eder S and Drach J: Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. Oncology. 85:223–227. 2013. View Article : Google Scholar : PubMed/NCBI
19	San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kroptt M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 359:906–917. 2008. View Article : Google Scholar : PubMed/NCBI
20	Wright JJ: Combination therapy of bortezomib with novel targeted agents: An emerging treatment strategy. Clinical Cancer Research. 16:4094–4104. 2010. View Article : Google Scholar : PubMed/NCBI
21	San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, et al: Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma and no increased risk of second primary malignancies: Final results of the phase 3 VISTA trial. Blood. 118:4762011.PubMed/NCBI
22	Hrusovsky I, Emmerich B, von Rohr A, Voegeli J, Taverna C, Olie RA, Pliskat H, Frohn C and Hess G: Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland. Oncology. 79:247–54. 2010. View Article : Google Scholar : PubMed/NCBI
23	Sher T, Ailawadhi S, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-llizaliturri FJ, Hong F, et al: A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol. 154:104–110. 2011. View Article : Google Scholar : PubMed/NCBI
24	Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmirili P, Bossi M, Oggioni N, D'Incalci M and De Coster R: Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. Exp Neurol. 204:317–325. 2007. View Article : Google Scholar : PubMed/NCBI
25	Csizmadia V, Raczynski A, Csizmadia E, Fedyk ER, Rottman J and Alden CL: Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover and induction in the neuronal cells in vitro. Neurotoxicology. 29:232–243. 2008. View Article : Google Scholar : PubMed/NCBI
26	Mangiacavalli S, Pochintesta L, Pascutto C, Cocito F, Cazzola M, Corso A and Pompa A: Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma. Am J Hematol. 88:102–106. 2013. View Article : Google Scholar : PubMed/NCBI
27	Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, et al: Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 116:4745–4753. 2010. View Article : Google Scholar : PubMed/NCBI
28	Moore S, Atwal S, Sachchithanantham S, Streetly M, Khan I, Percy L, Narat S, Rabin N, Johnston R, D'Sa S, et al: Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma. Eur J Haematol. 90:420–425. 2013. View Article : Google Scholar : PubMed/NCBI